Phenylacetic Acid

Phenylacetic Acid

SCHEMBL534930

O=C([O-])Cc1ccccc1.[Ag+]

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

folP

The experimentally established mechanism targets of Phenylacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 3/20 0.71
CES2 O00748 2/20 0.71
AKR1B1 P15121 1/20 0.64
FNTA P49354 1/20 0.58
FNTB P49356 1/20 0.58
HDAC8 Q9BY41 2/20 0.54
HDAC6 Q9UBN7 2/20 0.54
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
HDAC3 O15379 1/20 0.54
HDAC4 P56524 1/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC7 Q8WUI4 1/20 0.54
HDAC2 Q92769 1/20 0.54
HDAC10 Q969S8 1/20 0.54
HDAC11 Q96DB2 1/20 0.54
HDAC9 Q9UKV0 1/20 0.54
HDAC5 Q9UQL6 1/20 0.54
ALDH1A1 P00352 1/20 0.50
MAPK1 P28482 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenylacetic Acid SCHEMBL78312 0.95 CES1 (0.71) CES1CES2AKR1B1FNTAFNTB
Phenylacetic Acid SCHEMBL11772449 0.95 CES1 (0.71) CES1CES2AKR1B1FNTAFNTB
Phenylacetic Acid SCHEMBL6547052 0.95 CES1 (0.71) CES1CES2AKR1B1FNTAFNTB
Phenylacetic Acid SCHEMBL11248694 0.95 CES1 (0.71) CES1CES2AKR1B1FNTAFNTB
Phenylacetic Acid SCHEMBL3477184 0.95 CES1 (0.71) CES1CES2AKR1B1FNTAFNTB
Phenylacetic Acid SCHEMBL7214226 0.95 CES1 (0.71) CES1CES2AKR1B1FNTAFNTB
Phenylacetic Acid SCHEMBL1685642 0.95 CES1 (0.71) CES1CES2AKR1B1FNTAFNTB
Phenylacetic Acid SCHEMBL6930085 0.95 CES1 (0.71) CES1CES2AKR1B1FNTAFNTB
Phenylacetic Acid SCHEMBL62440 0.95 CES1 (0.71) CES1CES2AKR1B1FNTAFNTB
Phenylacetic Acid SCHEMBL8410214 0.95 CES1 (0.71) CES1CES2AKR1B1FNTAFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 935 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3596545-B1 SILVER-CONTAINING COMPOSITIONS CONTAINING CELLULOSIC POLYMERS AND USES EASTMAN KODAK CO (US) 2022-03-23 EP claimed
EP-3688773-A1 SILVER-CONTAINING NON-AQUEOUS COMPOSITION CONTAINING CELLULOSIC POLYMERS Eastman Kodak Company (US) 2020-08-05 EP claimed
EP-3596545-A1 SILVER-CONTAINING COMPOSITIONS CONTAINING CELLULOSIC POLYMERS AND USES Eastman Kodak Company (US) 2020-01-22 EP claimed
US-10370515-B2 Silver-containing non-aqueous composition containing cellulosic polymers EASTMAN KODAK COMPANY (US) 2019-08-06 US claimed
WO-2019060167-A1 SILVER-CONTAINING NON-AQUEOUS COMPOSITION CONTAINING CELLULOSIC POLYMERS EASTMAN KODAK COMPANY (US) 2019-03-28 WO claimed
US-20190092923-A1 SILVER-CONTAINING NON-AQUEOUS COMPOSITION CONTAINING CELLULOSIC POLYMERS BANK OF AMERICA, N.A., AS AGENT 2019-03-28 US claimed
EP-2753668-B1 CONDUCTIVE MATERIAL AND PROCESS Henkel IP & Holding GmbH (DE) 2019-03-27 EP claimed
EP-2625162-B1 METHODS OF MAKING L-ORNITHINE PHENYL ACETATE OCERA THERAPEUTICS INC (US) 2019-03-13 EP claimed
US-10173964-B2 L-ornithine phenyl acetate and methods of making thereof OCERA THERAPEUTICS, INC. (US) 2019-01-08 US claimed
WO-2018169672-A1 SILVER-CONTAINING COMPOSITIONS CONTAINING CELLULOSIC POLYMERS AND USES EASTMAN KODAK COMPANY (US) 2018-09-20 WO claimed
EP-2625162-A1 METHODS OF MAKING L-ORNITHINE PHENYL ACETATE Ocera Therapeutics Inc. (US) 2013-08-14 EP claimed
WO-2013036519-A1 CONDUCTIVE MATERIAL AND PROCESS HENKEL CORPORATION (US) 2013-03-14 WO claimed
WO-2012048043-A1 METHODS OF MAKING L-ORNITHINE PHENYL ACETATE OCERA THERAPEUTICS, INC. (US) 2012-04-12 WO claimed
EP-2413924-A1 L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF Ocera Therapeutics, INC. (US) 2012-02-08 EP claimed
US-20100280119-A1 L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF OCERA THERAPEUTICS, INC. (US) 2010-11-04 US claimed
WO-2010115055-A1 L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF OCERA THERAPEUTICS, INC. (US) 2010-10-07 WO claimed
WO-2007119966-A9 RESIN COMPOSITION COMPRISING CATALYST PRECURSOR FOR ELECTROLESS PLATING TO FORM ELECTROMAGNETIC WAVE SHIELDING LAYER, METHODS FOR FORMING METAL PATTERNS USING THE RESIN COMPOSITION AND METAL PATTERNS FORMED BY THE METHODS LG CHEMICAL LTD (KR) 2008-10-02 WO claimed
WO-2007119966-A1 RESIN COMPOSITION COMPRISING CATALYST PRECURSOR FOR ELECTROLESS PLATING TO FORM ELECTROMAGNETIC WAVE SHIELDING LAYER, METHODS FOR FORMING METAL PATTERNS USING THE RESIN COMPOSITION AND METAL PATTERNS FORMED BY THE METHODS LG CHEM, LTD. (KR) 2007-10-25 WO claimed
US-20070243363-A1 Resin composition comprising catalyst precursor for electroless plating to form electromagnetic wave shielding layer, methods for forming metal patterns using the resin composition and metal patterns formed by the methods LG CHEM, LTD. (KR) 2007-10-18 US claimed
US-4036650-A SILVER SALT, SILVER HALIDE, REDUCING AGENT CANON KABUSHIKI KAISHA (JA) 1977-07-19 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10370515-B2 Silver-containing non-aqueous composition containing cellulosic polymers PRKG1, PRKCB, PRKCA CES1 4498/4885CES2 3016/4885AKR1B1 2850/4885
US-20100280119-A1 L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF OAT, OTC, PYGL CES1 159/4885CES2 765/4885AKR1B1 167/4885
US-10173964-B2 L-ornithine phenyl acetate and methods of making thereof OAT, OTC, ODC1 CES1 149/4885CES2 761/4885AKR1B1 154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.